Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...

In the UK's National Health Service (NHS), it is crucial to ensure equitable access and improve outcomes for highly sensitised kidney transplant patients. This article discusses the challenges ...